evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 1 · 20%Very low 3 · 60%Low 1 · 20%Moderate 0 · 0%High 0 · 0%

Brain‐derived neurotrophic factor vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Cerebrospinal fluid filtration vs plasma exchange

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).

1 finding from 1 review

Eculizumab vs placebo

Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Interferon beta‐1a vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review